Jul

2026

VWF Replacement Products and Dosing

By William Aird

A Practical United States Guide for Clinicians

VWF replacement is not a single treatment.

Products differ in source, VWF activity, factor VIII content, regulatory indication, pediatric labeling, dosing structure, and the way they alter the linked kinetics of VWF and FVIII. A dose appropriate for one product or clinical setting should not be transferred automatically to another.

This guide addresses four VWF-containing products currently licensed in the United States:

Humate-P
Wilate
Vonvendi
Alphanate

It is designed for hematologists, trainees, pharmacists, anesthesiologists, surgeons, and clinicians developing acute, perioperative, or prophylactic treatment plans.

The central therapeutic distinction

Plasma-derived VWF/FVIII concentrates provide both proteins immediately, but repeated administration may lead to progressive FVIII accumulation.

Recombinant VWF separates VWF replacement from direct FVIII exposure, but that separation creates a different early challenge: immediate FVIII correction may require separate recombinant FVIII until endogenous FVIII rises.

The prescribing decision therefore has three dimensions:

what the patient lacks
what the clinical challenge requires
how the chosen product will behave over time

Everything that follows—product selection, dosing, timing, and monitoring—derives from those three questions.

Why this guide is United States-specific

VWF replacement products differ internationally in:

availability
approved indications
age restrictions
potency assignment
FVIII content
product labeling
recommended doses
laboratory terminology

Some high-purity plasma-derived VWF concentrates with little FVIII, widely discussed in European literature, are not licensed in the United States. Their omission from this guide is intentional rather than an oversight.

To reduce ambiguity, all product-specific indications and doses in this guide are based on current U.S. prescribing information. General treatment principles are informed by ASH/ISTH/NHF/WFH guidance and other major guidelines.

This is an educational guide, not a prescribing protocol. Verify the current FDA-approved prescribing information, vial potency, institutional policy, and hemophilia treatment center plan before treatment.

Scope of this guide

This guide focuses on replacement therapy for inherited VWD.

It does not provide comprehensive treatment protocols for:

acquired von Willebrand syndrome
pregnancy, delivery, or postpartum management
anti-VWF alloantibodies
angiodysplasia-directed therapy
continuous concentrate infusion
desmopressin
antifibrinolytic dosing

These situations may alter VWF recovery, clearance, dosing, treatment choice, or safety and require separate clinical guidance.

Continuous infusion of selected VWF/FVIII concentrates is used in some specialist centers during major surgery to reduce peak–trough fluctuation, but it is not a universal product-label strategy and should be undertaken only with an experienced treatment center and close laboratory monitoring.

First define the therapeutic task

Replacement is generally considered when desmopressin is ineffective, contraindicated, unavailable, too short-lived, or insufficient for the anticipated challenge. This commonly includes type 3 VWD, many patients with type 2 VWD, desmopressin nonresponders, and major or prolonged hemostatic challenges.

Before selecting a product or dose, ask five questions.

1. What is the challenge?

minor mucosal bleeding
major or life-threatening bleeding
elective minor procedure
elective major surgery
emergency surgery
recurrent bleeding requiring prophylaxis

2. Does the patient need an immediate rise in FVIII?

Patients with type 3 VWD—and some patients with type 2 or severe type 1 VWD—may have substantially reduced FVIII.

A patient with markedly reduced FVIII who is actively bleeding or undergoing urgent surgery may need immediate FVIII correction.

A VWF-only product stabilizes endogenous FVIII, but that rise is not instantaneous. Separate recombinant FVIII may therefore be needed with the initial infusion.

3. How long will replacement continue?

With repeated administration of a product containing both VWF and FVIII:

infused FVIII is supplied directly
endogenous FVIII is increasingly stabilized by infused VWF
FVIII may accumulate over time

The product that is useful for initial correction may not always be the ideal product for prolonged exposure.

FVIII accumulation is possible rather than inevitable. Its magnitude depends on the product, dose, interval, endogenous FVIII production, inflammation, surgical stress, and individual pharmacokinetics.

4. What does the current label permit?

The four products are not approved for identical uses.

Humate-P is approved for treatment of bleeding and perioperative management, but not routine prophylaxis.
Wilate is approved for on-demand treatment, perioperative management, and routine prophylaxis in adults and children.
Vonvendi is approved for on-demand and perioperative treatment in adults and children, but routine prophylaxis only in adults.
Alphanate has a restricted VWD indication for surgery or invasive procedures when desmopressin is ineffective or contraindicated. It is not indicated for severe type 3 VWD undergoing major surgery.¹

5. What will be monitored?

A replacement plan is incomplete unless it specifies:

clinical response
VWF activity
FVIII activity
timing of peak or trough measurements
repeat-dose interval
expected duration
criteria for dose adjustment
thrombosis and hypersensitivity surveillance

Kinetics at a glance

Product type	Immediate effect	What happens with repeated dosing	Central clinical risk
Plasma-derived VWF/FVIII	Supplies both VWF and FVIII immediately	Additional infused FVIII is combined with increasing stabilization of endogenous FVIII	Excessive FVIII exposure or accumulation
Recombinant VWF	Supplies VWF without FVIII	Endogenous FVIII rises as it is stabilized by infused VWF	An early FVIII gap when immediate correction is required

The distinction is not that one strategy is better.

It is that each solves a different kinetic problem.

At-a-glance product comparison

Product	Source and composition	Contains FVIII?	Approximate labeled VWF:FVIII relationship	Current U.S. VWD indications	Pediatric status	Central dosing consideration
Humate-P	Plasma-derived VWF/FVIII complex	Yes	Average VWF:RCo:FVIII ratio approximately 2.4:1	Spontaneous or trauma-induced bleeding; perioperative prevention of excessive bleeding	Bleeding and perioperative use approved in children	Relatively VWF-rich; FVIII must still be followed during repeated administration
Wilate	Plasma-derived VWF/FVIII complex	Yes	Approximately 1:1 VWF:RCo:FVIII activity ratio	On-demand treatment; perioperative management; routine prophylaxis	All three indications approved in children; age-specific dosing applies	Younger children may require higher weight-based doses; substantial FVIII is supplied with each VWF dose
Vonvendi	Recombinant VWF	No	No FVIII	On-demand treatment; perioperative management; adult routine prophylaxis	On-demand and perioperative use approved in children; pediatric prophylaxis not approved	Separate recombinant FVIII may be required initially if baseline FVIII is low or unknown
Alphanate	Plasma-derived VWF/FVIII complex	Yes	VWF:RCo:FVIII ratio varies by lot	Surgical or invasive procedures when desmopressin is ineffective or contraindicated	Surgical indication includes children	Restricted VWD indication; potency relationship must be checked with each lot

Do not compare products solely by the number of units on the vial.

VWF doses should be prescribed in the VWF activity units specified by the product label, not by FVIII units alone.

Choosing among products

A plasma-derived VWF/FVIII product may be attractive when:

an immediate increase in both VWF and FVIII is needed
baseline FVIII is markedly reduced
the patient is actively bleeding
emergency surgery does not allow time for endogenous FVIII to rise
the product has previously produced reliable recovery and clinical hemostasis

Recombinant VWF may be attractive when:

avoiding direct FVIII exposure is desirable
repeated dosing could lead to excessive FVIII levels
the patient has adequate baseline FVIII
elective timing allows endogenous FVIII to rise after VWF administration
separate recombinant FVIII can be administered when immediate FVIII correction is needed
avoidance of a plasma-derived product is a patient priority

Product selection should also consider:

previous response
measured recovery
VWF half-life
baseline and evolving FVIII
bleeding site
procedure
age
thrombotic risk
venous access
vial sizes and treatment burden
local availability
payer restrictions
treatment-center experience

No product is universally superior.

That conclusion is an inference from product heterogeneity and the absence of robust head-to-head trials establishing one replacement product as best across all clinical settings.²

A note on units and calculation

VWF activity units

FDA labels continue to express replacement doses in VWF:RCo activity units, even though many clinical laboratories now use newer platelet-dependent assays such as VWF:GPIbM or VWF:GPIbR.

Prescribe and calculate the dose using the potency stated on the product vial and in its prescribing information.

The assay used for clinical monitoring should be documented with the result.

VWF:RCo, VWF:GPIbM, and VWF:GPIbR values are related measures of platelet-dependent activity, but they are not analytically identical. When possible:

follow the same assay serially
interpret results using that laboratory’s method and reference system
avoid treating a VWF:GPIbM value as though it were automatically interchangeable with a VWF:RCo target
involve an experienced coagulation laboratory when assay results and clinical response disagree³

General recovery principle

Several labels use an assumed incremental recovery of approximately:

2 IU/dL increase in VWF activity for each 1 IU/kg infused

This is a label-based estimate, not a universal biologic constant.

Actual recovery may differ because of:

age
body size
blood volume
active bleeding
rapid clearance
VWD subtype
inflammation
inhibitor or alloantibody
product-specific pharmacokinetics

Recovery may be lower in young children.

When individual recovery is known, use it.

When it is not known, the relevant product label may permit an assumed recovery for initial dose calculation.

General loading-dose equation

For products using an incremental-recovery calculation:

Required VWF activity units = body weight × desired rise in VWF activity ÷ incremental recovery

Where:

body weight is in kilograms
desired rise is target minus baseline VWF activity in IU/dL
recovery is expressed as IU/dL rise per IU/kg infused

For an assumed recovery of 2 IU/dL per IU/kg:

Required units = body weight × desired rise × 0.5

Worked example

A 70-kg patient has a baseline VWF activity of 10 IU/dL and a target of 100 IU/dL.

Desired rise:

90 IU/dL

Estimated dose:

70 × 90 × 0.5 = 3,150 VWF activity units

This calculation estimates the starting dose.

Recovery tests whether the assumption was correct.

Humate-P

Product profile

Humate-P is a plasma-derived concentrate containing both VWF and FVIII. Its average VWF:RCo-to-FVIII activity ratio is approximately 2.4:1. Each vial is labeled with both VWF:RCo and FVIII activity.⁴

U.S. indications

Humate-P is indicated in adults and children with VWD for:

treatment of spontaneous bleeding
treatment of trauma-induced bleeding
prevention of excessive bleeding during and after surgery

For patients with mild or moderate VWD, the indication applies when desmopressin is known or suspected to be inadequate.

It is not FDA-approved for routine prophylaxis against spontaneous VWD bleeding.⁵

Humate-P: treatment of bleeding episodes

Minor bleeding

Examples include uncomplicated epistaxis, oral bleeding, and heavy menstrual bleeding.

For mild type 1 VWD, desmopressin is generally considered first when it is effective and safe. Humate-P is used when desmopressin is known or suspected to be inadequate.

Clinical setting	Labeled initial approach
Minor bleeding in VWD when concentrate is indicated	40–50 IU VWF:RCo/kg for 1 or 2 doses

The identical labeled range across VWD types is shown as a single row because the dose distinction lies primarily in the severity and clinical context rather than in separate minor-bleed ranges.

Major bleeding

Examples include severe or refractory epistaxis, gastrointestinal bleeding, central nervous system trauma, hemarthrosis, and major traumatic bleeding.

VWD category	Loading dose	Subsequent dosing
Mild type 1 VWD when desmopressin is inappropriate or inadequate	40–60 IU VWF:RCo/kg	40–50 IU/kg every 8–12 hours for 3 days to maintain trough VWF:RCo above 50 IU/dL; then 40–50 IU/kg daily, for up to 7 total days
Moderate or severe type 1 VWD	50–75 IU VWF:RCo/kg	40–60 IU/kg every 8–12 hours for 3 days to maintain trough VWF:RCo above 50 IU/dL; then 40–60 IU/kg daily, for up to 7 total days
Type 2 or type 3 VWD	60–80 IU VWF:RCo/kg	40–60 IU/kg every 8–12 hours for 3 days to maintain trough VWF:RCo above 50 IU/dL; then 40–60 IU/kg daily, for up to 7 total days

FVIII activity should be monitored during treatment, especially when repeated doses are administered.⁶

Humate-P: surgery

Preoperative targets

Procedure	Target peak VWF activity	Target peak FVIII
Major surgery	100 IU/dL	80–100 IU/dL
Minor or oral surgery	50–60 IU/dL	40–50 IU/dL

When individual incremental recovery is available:

Loading dose = desired VWF rise × body weight ÷ individual recovery

When recovery is unavailable, the label assumes a VWF recovery of 2 IU/dL per IU/kg.

For emergency surgery, the labeled loading dose is:

50–60 IU VWF:RCo/kg

The loading dose is administered 1–2 hours before surgery.

Maintenance dosing

The initial maintenance dose is generally one-half of the loading dose.

Procedure	Early postoperative target troughs	Later target troughs	Minimum labeled treatment duration
Major surgery	VWF activity and FVIII above 50 IU/dL for up to 3 days	Both above 30 IU/dL after day 3, as needed	At least 72 hours
Minor surgery	VWF activity at least 30 IU/dL; FVIII above 30 IU/dL	Individualized	At least 48 hours
Oral surgery as defined in the label	VWF activity at least 30 IU/dL; FVIII above 30 IU/dL	Usually not applicable	At least one postoperative maintenance dose; approximately 8–12 hours

The label states that perioperative trough levels of either VWF:RCo or FVIII should not exceed 100 IU/dL.

This is a trough safety limit, not the preoperative peak target.

A preoperative VWF peak target of 100 IU/dL for major surgery is therefore not inconsistent with avoiding postoperative troughs above 100 IU/dL.

Maintenance doses are often given every 8–12 hours initially and adjusted according to measured troughs and individual pharmacokinetics.⁷

Important interpretation

The product label’s perioperative targets predate the 2021 ASH/ISTH/NHF/WFH guideline.

The guideline conditionally suggests targeting both VWF activity and FVIII activity at or above 0.50 IU/mL for at least 3 days after major surgery, with targets and duration individualized to the patient and procedure.⁸

The label and guideline should therefore be used together:

the label determines product-specific dosing
the guideline informs the broader clinical objective
serial measurements determine whether the plan is working

Wilate

Product profile

Wilate is a plasma-derived concentrate containing VWF and FVIII. The labeled VWF:RCo-to-FVIII activity ratio is approximately 1:1.⁹

U.S. indications

Wilate is indicated in adults and children with VWD for:

on-demand treatment and control of bleeding
perioperative management
routine prophylaxis to reduce bleeding frequency

The July 2026 label establishes safety and effectiveness for routine prophylaxis in children younger than 6 years and provides age-specific dosing.¹⁰

Wilate: treatment of bleeding episodes

Patients 6 years and older

Bleeding severity	Target trough for VWF activity and FVIII	Loading dose	Maintenance dose	Interval	Typical duration
Minor	Above 30 IU/dL	20–40 IU VWF:RCo/kg	20–30 IU/kg	Every 12–24 hours	Up to 3 days
Major	Above 50 IU/dL	40–60 IU VWF:RCo/kg	20–40 IU/kg	Every 12–24 hours	Up to 5–7 days

Children younger than 6 years

Bleeding severity	Target trough for VWF activity and FVIII	Loading dose	Maintenance dose	Interval	Typical duration
Minor	Above 30 IU/dL	30–50 IU VWF:RCo/kg	30–40 IU/kg	Every 12–24 hours	Up to 3 days
Major	Above 50 IU/dL	50–80 IU VWF:RCo/kg	30–50 IU/kg	Every 12–24 hours	Up to 5–7 days

The dose and duration should be adjusted according to:

site and severity of bleeding
clinical response
VWF activity
FVIII activity
pharmacokinetics

Type 3 VWD with gastrointestinal bleeding may require greater exposure than uncomplicated bleeding.¹¹

Wilate: surgery

Procedure	Loading dose within 3 hours before surgery	Target peak VWF activity	Maintenance dose	Target trough VWF activity	Interval and duration
Minor surgery	30–60 IU VWF:RCo/kg	50 IU/dL	15–30 IU/kg or one-half of loading dose	Above 30 IU/dL	Every 12–24 hours until healing, generally up to 3 days
Major surgery	40–60 IU VWF:RCo/kg	100 IU/dL	20–40 IU/kg or one-half of loading dose	Above 50 IU/dL	Every 12–24 hours; at least 2 doses during the first 24 hours; continue until healing, generally up to 6 days or longer

When possible:

determine individual VWF recovery before surgery
measure VWF activity and FVIII at least daily after surgery
adjust the dose or interval to maintain hemostatic levels

The Wilate label states that perioperative FVIII activity should not exceed 250% to reduce thrombotic risk.¹²

This upper safety limit should not be interpreted as a desired target.

The objective is the lowest exposure that reliably supports hemostasis.

Wilate: routine prophylaxis

Age	Labeled dose	Frequency
6 years and older	20–40 IU/kg	Two or three times weekly
Younger than 6 years	30–50 IU/kg	Two or three times weekly

Individualize prophylaxis according to:

bleeding phenotype
age
previous bleeding frequency
bleeding site
response
pharmacokinetics
breakthrough bleeding
treatment burden

The prophylaxis indication applies across VWD types, but the need for prophylaxis is determined by bleeding burden rather than subtype alone.

Evidence for VWD prophylaxis is less extensive than the evidence base for hemophilia prophylaxis. The 2021 guideline recommendation is conditional and based on low-certainty evidence, although subsequent studies and current product labeling have expanded practical options.¹³

Vonvendi

Product profile

Vonvendi is recombinant VWF and contains no FVIII.

This creates an important separation:

VWF is supplied directly
endogenous FVIII is stabilized and rises over time
immediate FVIII correction is not guaranteed
recombinant FVIII can be added selectively

Vonvendi contains ultra-large VWF multimers because it is not exposed to ADAMTS13 during manufacture. After infusion, these multimers enter the patient’s circulation and undergo physiologic processing, including cleavage by endogenous ADAMTS13.

The presence of ultra-large multimers is a product characteristic, not a reason to alter labeled dosing independently of clinical and laboratory monitoring.¹⁴

U.S. indications

Vonvendi is indicated in adults and children for:

on-demand treatment and control of bleeding
perioperative management

It is also indicated for:

routine prophylaxis in adults

Routine prophylaxis is not FDA-approved for pediatric patients.¹⁵

When should recombinant FVIII be added?

With the first Vonvendi dose, administer an approved recombinant FVIII product when:

baseline FVIII activity is below 40 IU/dL, or
baseline FVIII is unknown and immediate hemostasis is required

When an immediate FVIII rise is not required, Vonvendi may be given alone.

Depending on baseline FVIII, one Vonvendi infusion is expected to raise endogenous FVIII activity above 40 IU/dL within approximately 6 hours.

With repeated dosing:

monitor FVIII
do not assume recombinant FVIII remains necessary
stop separate FVIII once endogenous FVIII has reached the required level

Vonvendi and recombinant FVIII are separate products with separate potency labels.

Calculate each independently.

Vonvendi: treatment of bleeding episodes

Bleeding severity	Initial Vonvendi dose	Subsequent dose
Minor	40–50 IU VWF:RCo/kg	40–50 IU/kg every 8–24 hours as clinically required
Major	50–80 IU VWF:RCo/kg	40–60 IU/kg every 8–24 hours for approximately 2–3 days

For major bleeding:

the initial dose should produce a VWF activity above 60 IU/dL
maintain trough VWF activity above 50 IU/dL for as long as clinically necessary
if baseline FVIII is below 40 IU/dL or unknown, administer recombinant FVIII
when baseline FVIII is unknown in a major bleed, the label recommends an FVIII target peak of 80–100 IU/dL

Administer the complete Vonvendi dose first, followed by recombinant FVIII within 10 minutes when both are required.¹⁶

Vonvendi: elective surgery

A distinctive feature of Vonvendi is the option to administer a dose 12–24 hours before surgery, allowing endogenous FVIII to rise before the immediate preoperative dose.

Before surgery:

obtain baseline FVIII
consider a Vonvendi dose 12–24 hours preoperatively
reassess FVIII within 3 hours of surgery
give recombinant FVIII with the immediate preoperative dose if the target FVIII has not been reached

Minimum FVIII before the immediate preoperative dose

Procedure	Minimum FVIII activity
Minor surgery	30 IU/dL
Major surgery	60 IU/dL

If FVIII has reached the minimum, Vonvendi may be given alone within 1 hour before surgery.

If FVIII remains below the minimum, administer Vonvendi followed by recombinant FVIII.

This strategy is not a desmopressin trial, but the reasoning is similar: measure the patient’s biologic response rather than assume that endogenous FVIII has risen sufficiently.

Vonvendi: preoperative peak targets

Procedure	Target peak VWF activity	Target peak FVIII
Minor surgery	50–60 IU/dL	40–50 IU/dL
Major surgery	100 IU/dL	80–100 IU/dL

The preoperative Vonvendi dose may be calculated as:

Desired VWF rise × body weight ÷ individual incremental recovery

If individual recovery is unavailable, the label permits assuming recovery of 2 IU/dL per IU/kg.

Vonvendi: emergency surgery

When baseline values and individual recovery are unavailable, the label provides surgery-specific empirical guidance.

Procedure	Empirical Vonvendi dose	Empirical recombinant FVIII dose
Minor surgery	25–30 IU/kg	20–25 IU/kg when required
Major surgery	50 ± 10 IU/kg	40–50 IU/kg when required

The label also presents broader perioperative Vonvendi dosing ranges of approximately 40–60 IU/kg in settings where clinical and laboratory information is limited.

The surgery-specific empirical table should be used when its assumptions match the clinical situation. The actual recombinant FVIII dose should be individualized according to:

baseline FVIII
target FVIII
urgency
clinical challenge
the prescribing information for the selected recombinant FVIII product¹⁷

Vonvendi: postoperative management

Procedure	VWF trough target during first 72 hours	VWF trough after 72 hours	FVIII trough target during first 72 hours	FVIII trough after 72 hours	Minimum duration
Minor surgery	At least 30 IU/dL	Not specified	Above 30 IU/dL	Not specified	48 hours
Major surgery	Above 50 IU/dL	Above 30 IU/dL	Above 50 IU/dL	Above 30 IU/dL	72 hours

Postoperative dosing may range from every 12–24 hours to every other day, depending on:

clinical hemostasis
VWF activity
FVIII activity
procedure
wound healing
individual kinetics

Continue to monitor both VWF and FVIII after surgery.¹⁸

Vonvendi: routine prophylaxis in adults

The labeled starting regimen is:

40–60 IU/kg twice weekly

Treat breakthrough bleeds according to the on-demand dosing recommendations.

The dose and interval may subsequently be individualized according to:

bleeding frequency
bleeding site
breakthrough bleeding
pharmacokinetics
treatment burden
patient goals

Pediatric prophylaxis is not currently an FDA-approved Vonvendi indication.

Alphanate

Product profile

Alphanate is a plasma-derived VWF/FVIII complex.

The ratio of VWF:RCo to FVIII varies by lot. The VWF and FVIII potency printed on the specific vial and carton must therefore be reviewed whenever the lot changes.¹⁹

Restricted U.S. VWD indication

Alphanate is indicated for surgical or invasive procedures in adults and children with VWD when desmopressin is:

ineffective, or
contraindicated

It is not indicated for severe type 3 VWD undergoing major surgery.

It is not FDA-approved for:

routine treatment of spontaneous VWD bleeding
routine VWD prophylaxis²⁰

Alphanate: minor surgery or invasive procedures

Population	Preoperative dose	Maintenance dose	Interval	Duration
Adults	60 IU VWF:RCo/kg	40–60 IU/kg	Every 8–12 hours	As clinically needed for 1–3 days
Children	75 IU VWF:RCo/kg	50–75 IU/kg	Every 8–12 hours	As clinically needed for 1–3 days

Labeled goals:

preoperative FVIII activity: 40–50 IU/dL
trough VWF activity: above 50 IU/dL
trough FVIII activity: above 50 IU/dL
VWF and FVIII safety ceiling: should not exceed 150 IU/dL

Measure peak and trough VWF and FVIII at least daily.

Alphanate: major surgery

Do not use for severe type 3 VWD undergoing major surgery.

For other eligible adults and children:

Population	Preoperative dose	Maintenance dose	Interval	Duration
Adults	60 IU VWF:RCo/kg	40–60 IU/kg	Every 8–12 hours	At least 3–7 days, as clinically needed
Children	75 IU VWF:RCo/kg	50–75 IU/kg	Every 8–12 hours	At least 3–7 days, as clinically needed

Labeled goals:

preoperative FVIII activity: 100 IU/dL
trough VWF activity: above 50 IU/dL
trough FVIII activity: above 50 IU/dL
VWF and FVIII safety ceiling: should not exceed 150 IU/dL

Because the VWF:RCo-to-FVIII ratio varies by lot, prescribing solely by FVIII potency can produce an unintended VWF dose.²¹

Product-specific safety ceilings are not interchangeable

The product labels use different safety language:

Product	Relevant labeled ceiling
Humate-P	Perioperative trough VWF:RCo or FVIII should not exceed 100 IU/dL
Wilate	Perioperative FVIII activity should not exceed 250%
Alphanate	VWF and FVIII should not exceed 150 IU/dL

These differences reflect product-specific labels rather than a universal biologic threshold.

Do not carry the safety ceiling from one product into the dosing plan for another.

A label ceiling is also not a therapeutic target. Aim for the lowest level that reliably supports hemostasis while limiting excessive exposure.

Monitoring replacement therapy

What to measure

For clinically significant bleeding, major procedures, repeated dosing, or prophylaxis assessment, monitor:

VWF activity
FVIII activity
hemoglobin and blood loss when relevant
platelet count when clinically indicated
clinical bleeding
wound and drain output
transfusion requirement
breakthrough bleeding
infusion reactions
signs of thrombosis

Complex monitoring should be performed with an experienced coagulation laboratory whenever possible.

Peak versus trough

Peak levels help answer:

Did the expected recovery occur?
Was the preoperative target reached?
Does unexpectedly poor recovery suggest underdosing, assay error, rapid clearance, or an inhibitor?

Trough levels help answer:

Is hemostatic coverage lasting until the next dose?
Should the interval be shortened?
Is FVIII accumulating?
Can treatment be spaced or stopped?

During prolonged therapy, the trough often becomes more clinically useful than repeated peak measurements.

Suggested monitoring framework

Situation	Suggested monitoring approach
Uncomplicated minor bleed treated with one dose	Assess clinical response; repeat laboratory testing may not be required after every dose if prior recovery is established and the event is minor
Major bleed	Obtain baseline VWF and FVIII when feasible; repeat after initial treatment; obtain serial troughs before subsequent doses
Minor procedure requiring repeated replacement	Confirm perioperative target; reassess VWF and FVIII according to expected duration and bleeding risk
Major surgery	Obtain baseline levels and preoperative peak; measure VWF and FVIII at least daily, and more frequently during unstable bleeding or early intensive dosing
Routine prophylaxis	Track bleeding episodes, infusion burden, adherence, breakthrough bleeding, and iron status when relevant; obtain periodic factor levels or pharmacokinetic assessment when results will change management
Poor response	Confirm dose, vial potency, administration, sampling time, assay, recovery, clearance, local source of bleeding, and possible inhibitor

The minor-bleed and prophylaxis rows represent practical synthesis rather than rigid guideline requirements. Monitoring intensity should be proportional to risk and to the likelihood that a result will alter management.²²

Integrating guideline targets with product labels

The ASH/ISTH/NHF/WFH guideline suggests:

targeting both VWF activity and FVIII activity at or above 0.50 IU/mL for at least 3 days after major surgery
adding tranexamic acid to factor replacement or desmopressin for many minor procedures
considering tranexamic acid alone for selected patients with mild type 1 VWD undergoing minor mucosal procedures
using long-term prophylaxis for patients with severe and frequent recurrent bleeding
reassessing the need for prophylaxis periodically²³

The major-surgery recommendation is conditional and based on very-low-certainty evidence. It should not be converted into a rigid universal threshold without considering the procedure, bleeding phenotype, local laboratory access, and patient-specific risk.

These recommendations do not create a universal dose.

The product label specifies how that particular concentrate is dosed.

The guideline specifies what broader clinical objective should be achieved.

The patient’s levels and clinical course determine whether either has been accomplished.

Adjunctive treatment still matters

Replacement corrects circulating VWF and supports FVIII.

It does not eliminate:

local anatomy
tissue injury
fibrinolysis
endometrial pathology
angiodysplasia
surgical technique
infection
medication effects

For mucosal procedures and bleeding, consider:

systemic or topical tranexamic acid
dental packing
gelatin sponges
fibrin sealants
suturing
cautery
gynecologic therapy
endoscopic treatment
other site-specific hemostatic measures

The tranexamic acid dose, route, and duration depend on age, renal function, bleeding site, procedure, thrombosis risk, and local protocol. Use the dedicated antifibrinolytic guide or current institutional protocol rather than treating tranexamic acid as a single universal dose.

More VWF is not always the answer to continued bleeding.²⁴

Safety considerations

Thromboembolic risk

Thrombotic events have been reported with VWF replacement, particularly when:

FVIII becomes markedly elevated
repeated VWF/FVIII dosing continues for several days
the patient has additional thrombotic risk factors
surgery, immobility, cancer, pregnancy, or inflammation contributes to risk

FVIII accumulation is not inevitable with every product or prophylaxis regimen, but it must be considered during repeated or intensive treatment.

Monitor FVIII during repeated treatment and provide thromboprophylaxis when otherwise clinically indicated after adequate hemostatic correction.²⁵

Hypersensitivity

All products can cause hypersensitivity reactions.

Stop the infusion and treat appropriately if the patient develops:

urticaria
wheezing
hypotension
chest tightness
angioedema
anaphylaxis

Vonvendi is contraindicated in patients with a history of life-threatening hypersensitivity to Vonvendi or its components, including mouse or hamster proteins.²⁶

VWF inhibitors

Consider an anti-VWF alloantibody, particularly in type 3 VWD, when there is:

unexpectedly poor recovery
rapid loss of response
persistent bleeding despite apparently adequate dosing
infusion reaction
anaphylaxis

In suspected alloantibody-associated anaphylaxis, additional exposure to a VWF-containing concentrate may be dangerous.

Management should occur through a specialized bleeding-disorder treatment center.²⁷

Plasma-derived products

Humate-P, Wilate, and Alphanate are derived from human plasma.

Manufacturing includes donor screening and pathogen-reduction measures, but the theoretical risk of transmitting infectious agents cannot be eliminated completely.²⁸

Common prescribing errors

Error 1: Dosing by FVIII units instead of VWF activity units

The vial may show both.

For VWD, prescribe the intended VWF activity dose.

Error 2: Assuming every VWF product has the same amount of FVIII

Humate-P, Wilate, and Alphanate contain FVIII in different proportions.

Vonvendi contains none.

Error 3: Forgetting immediate FVIII needs with recombinant VWF

If FVIII is low or unknown and immediate hemostasis is required, add recombinant FVIII with the first Vonvendi dose.

Error 4: Continuing recombinant FVIII automatically with every Vonvendi dose

Endogenous FVIII rises after VWF replacement.

Recheck it.

Error 5: Ignoring possible FVIII accumulation with repeated VWF/FVIII

concentrate

The patient produces FVIII normally.

Infused VWF stabilizes it.

Error 6: Transferring a dose or safety ceiling from one product to another

Even when products are expressed in VWF:RCo units, their approved indications, FVIII exposure, recovery, intervals, targets, and ceilings differ.

Error 7: Treating a target rather than the patient

A satisfactory level does not exclude:

uncontrolled local bleeding
angiodysplasia
surgical bleeding
hyperfibrinolysis
another hemostatic defect

Error 8: Treating the patient but not the challenge

A regimen adequate for epistaxis may be inadequate for major abdominal surgery.

Error 9: Treating the challenge but not the kinetics

A correct peak does not guarantee a sufficient trough.

Error 10: Using Alphanate outside its restricted VWD indication

Its U.S. VWD indication is limited to surgical and invasive procedures when desmopressin is ineffective or contraindicated and excludes severe type 3 VWD undergoing major surgery.

Practical bedside sequence

When replacement is being considered:

Confirm that VWF replacement is actually needed.
Define the bleeding or procedural challenge.
Obtain baseline VWF activity and FVIII when feasible.
Determine whether immediate FVIII correction is required.
Select a product whose composition and indication fit the task.
Dose in the VWF activity units listed for that product.
Add local and antifibrinolytic treatment when appropriate.
Measure clinical response.
Follow VWF and FVIII during major or repeated treatment.
Adjust the dose, interval, duration, product, or therapeutic mechanism when the response is inadequate.

Clinical synthesis

VWF replacement does more than raise a laboratory value.

It restores platelet adhesion, stabilizes endogenous FVIII, and changes the kinetics of hemostasis over time.

Plasma-derived VWF/FVIII concentrates provide both proteins immediately, but repeated dosing may lead to progressive FVIII accumulation.

The prescribing decision therefore has three dimensions:

what the patient lacks
what the clinical challenge requires
how the chosen product will behave over time

The correct dose is not merely a number in units per kilogram.

It is a starting hypothesis.

Recovery tests whether the dose reached the circulation.

Trough levels test whether it lasted.

Clinical hemostasis tests whether it mattered.

The best replacement plan matches the product to the patient, the challenge, and the kinetics—and then keeps measuring until the need for replacement has passed.

Source status

Product-specific indications, dosing, age restrictions, safety ceilings, and contraindications were derived from current U.S. prescribing information:

Humate-P: DailyMed label updated August 2020; reviewed July 2026
Wilate: prescribing information revised July 2026
Vonvendi: prescribing information revised September 2025
Alphanate: DailyMed record updated May 2025; reviewed July 2026

Broader treatment principles, perioperative targets, monitoring strategy, use of adjunctive therapy, and interpretation of replacement response were informed by:

ASH/ISTH/NHF/WFH 2021 guideline on management of von Willebrand disease
BSH/UKHCDO guidance
2024 BSH laboratory guideline
NHLBI guidance
Nordic guidance
Italian expert guidance
relevant pharmacokinetic, prophylaxis, and perioperative studies

Product labels determine product-specific dosing. Guidelines inform clinical targets, monitoring, and treatment strategy.

Because product labeling and guideline recommendations may change, the online version of this guide should display:

Last reviewed: July 2026

Both product labels and major guidelines should be rechecked periodically.

Stay Updated

If you are interested in getting the latest articles from The Blood Project, enter your name and email